Important Dates

no event

Latest News

Prizes awarded to Factor-H

Congratulations to Factor-H for the hugely well-deserved recognition of their work from Amgen (2024 Amgen/MIT Solve award) and MDS (Public Service Award). Read more here: Factor-H is Awarded the 2024 Amgen Prize! and Factor-H President receives the 2024 Public Service Award from the MDS. […]

Read More…

Alnylam Pharmaceuticals Global study endorsed* by EHDN

Study aims and goal: ALN-HTT02 is a novel C16-siRNA conjugate for huntingtin-lowering. This Phase Ib study aims to evaluate ALN-HTT02 in adults with Huntington’s Disease. No. of study participants and sites: The study plans to enrol participants from ~20 sites in Canada, Germany, UK and US. For further information see the clinical trial registration. *EHDN […]

Read More…